Division of Hematology-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Blood. 2010 Dec 9;116(24):5217-27. doi: 10.1182/blood-2010-04-281568. Epub 2010 Sep 15.
HGAL is a germinal center (GC)-specific gene that negatively regulates lymphocyte motility and whose expression predicts improved survival of patients with diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL). We demonstrate that HGAL serves as a regulator of the RhoA signaling pathway. HGAL enhances activation of RhoA and its down-stream effectors by a novel mechanism - direct binding to the catalytic DH-domain of the RhoA-specific guanine nucleotide exchange factors (RhoGEFs) PDZ-RhoGEF and LARG that stimulate the GDP-GTP exchange rate of RhoA. We delineate the structural domain of HGAL that mediates its interaction with the PDZ-RhoGEF protein. These observations reveal a novel molecular mechanism underlying the inhibitory effects of GC-specific HGAL protein on the motility of GC-derived lymphoma cells. This mechanism may underlie the limited dissemination and better outcome of patients with HGAL-expressing DLBCL and cHL.
HGAL 是生发中心(GC)特异性基因,可负向调节淋巴细胞的迁移,其表达可预测弥漫性大 B 细胞淋巴瘤(DLBCL)和经典霍奇金淋巴瘤(cHL)患者的生存改善。我们证明 HGAL 是 RhoA 信号通路的调节剂。HGAL 通过一种新的机制增强 RhoA 的激活及其下游效应子的活性 - 直接与 RhoA 特异性鸟嘌呤核苷酸交换因子(RhoGEFs)PDZ-RhoGEF 和 LARG 的催化 DH 结构域结合,刺激 RhoA 的 GDP-GTP 交换率。我们描绘了介导 HGAL 与其 PDZ-RhoGEF 蛋白相互作用的结构域。这些观察结果揭示了 GC 特异性 HGAL 蛋白对 GC 衍生淋巴瘤细胞迁移的抑制作用的新分子机制。该机制可能是 HGAL 表达的 DLBCL 和 cHL 患者传播受限和预后较好的基础。